

Press Release



Agreement for Drospirenone

TOKYO, June 20, 2022 - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter referred to as “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. announces that ASKA and Hyundai Pharm. Co., Ltd (Head Office: Seoul, Republic of Korea, hereinafter referred to as “Hyundai Pharm”) have concluded an Agreement to grant exclusive rights to develop and market the oral contraceptive drug, drospirenone as a sole Active Pharmaceutical Ingredient (hereinafter referred to as “Product”) for the territory of Korea.

ASKA had acquired exclusive rights to develop and market the Product for the territories of Japan and Korea from Insud Pharma (Head Office: Madrid, Spain, hereinafter referred to as “Insud Pharma”) in January 2020. In the United States and Europe, Marketing Approvals of the Product were granted in 2019 under the brand name “SLYND®” and “SLINDA®” respectively and Insud Pharma has commercialized the product in these countries through Exeltis, its branded pharmaceutical unit focused on Women’s Health. ASKA is conducting Phase III Clinical Development of the Product in Japan.

Under the terms of this Agreement, ASKA will receive an upfront and further milestone and other payments for the exclusive development and marketing rights in Korea from its partner Hyundai. Financial terms of the Agreement were not disclosed.

ASKA hopes to provide an alternative opportunity for Korean women who want innovative contraceptive pills through this transaction with Hyundai Pharm and we are looking forward to a strong partnership. The Company’s intention is to make a further contributions to the healthy future for women by bringing such Products as a specialty pharmaceutical leader in the field of women’s health in Japan and Asia.

About Hyundai Pharm

Hyundai Pharm (<http://www.hyundaipharm.co.kr/english/index.jsp>) is a pharmaceutical company with its Head Office in Seoul, Republic of Korea. Hyundai Pharm is currently expanding its women’s health portfolio to be a leading company in the area. Hyundai believes the Product will contribute to unmet medical needs for women.

About Insud Pharma

Insud Pharma (<https://www.insudpharma.com/en/>) is a leading Spanish company with a track record in the pharmaceutical and healthcare industry spanning over 40 years. With 7,000 employees in 40 countries, Insud Pharma's contribution to global public health is enormous, thanks to the medicines and APIs developed and manufactured at its three highly synergic business units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience).

About Exeltis

Exeltis (<https://www.exeltis.com/>) is a fast-growing division of the integrated health sciences group Insud Pharma. It boasts a leadership position in the Women's Health segment, and is constantly innovating and seeking new treatments and devices to improve women's health and wellbeing around the world.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp